GS-4571

Phase 1Small molecule

Gilead

GS-4571 is one of 41 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Weight ManagementRecruiting

Type 2 Diabetes MellitusPhase 1

Active, not recruiting

Weight ManagementPhase 1

Recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Preclinical

20 2

Tanzeum

GSK

Preclinical

10 3

Insulin 320

Novo Nordisk

Preclinical

43 4

Adenocard

Astellas

Preclinical

1 5

Cipro

Myrbetriq

Golytely

Lixisenatide

4 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 10

Glargine

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Weight Management

NCT06562907

Clinical

Trials by Indication[1]

Weight Management1 trial

A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Oral Doses of GS-4571 in Healthy Participants, Multiple Ascending Oral Doses of GS-4571 in Nondiabetic Obese Participants and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM), and to Evaluate the Effect of Food and an Acid-Reducing Agent on Pharmacokinetics of GS-4571

Recruiting· Gilead logo

Gilead·Phase 1·NCT06562907·134 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GS-4571. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GS-4571 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GS-4571. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Gilead

GS-4571

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Weight Management1 trial

References

Drug Info

Quick Facts

Related News